SPECIAL FEATURES

CCR Translations

2121 Biomarkers for EGFR-Antagonist Response: In the Genes and on the Genes! Hariharan Easwaran and Stephen B. Baylin See article p. 2360

2124 Double Down for a Double Win Pearl S. Huang See article p. 2316

2127 Competing Risk Analyses: How Are They Different and Why Should You Care? Rick Chappell See article p. 2301

2130 Choosing Phase II Endpoints and Designs: Evaluating the Possibilities Michael LeBlanc and Catherine Tangen See article p. 2309

Molecular Pathways

2133 Molecular Pathways: Digoxin Use and Estrogen-Sensitive Cancers—Risks and Possible Therapeutic Implications Robert J. Biggar

2138 Molecular Pathways: Pathogenesis and Clinical Implications of Microbiome Alteration in Esophagitis and Barrett Esophagus Liying Yang, Fritz Francois, and Zhiheng Pei

Review

2145 Novel Therapeutic Agents for the Management of Patients with Multiple Myeloma and Renal Impairment Asher A. Chanan-Khan, Jesús F. San Miguel, Sundar Jagannath, Heinz Ludwig, and Meletios A. Dimopoulous

HUMAN CANCER BIOLOGY

Expression of Epstein-Barr Virus–Encoded Proteins in Extranodal NK/T-cell Lymphoma, Nasal Type (ENKL): Differences in Biologic and Clinical Behaviors of LMP1-Positive and -Negative ENKL Naoko Kanemitsu, Yasushi Isobe, Azuchi Masuda, Shuji Momose, Morihiro Higashi, Jun-ichi Tamaru, Koichi Sugimoto, and Norio Komatsu


First Evidence That γ-Tocotrienol Inhibits the Growth of Human Gastric Cancer and Chemosensitizes It to Capecitabine in a Xenograft Mouse Model through the Modulation of NF-κB Pathway
Kanjoormana A. Manu, Muthu K. Shanmugam, Lalitha Ramachandran, Feng Li, Chee Wui Fong, Alan Prem Kumar, Patrick Tan, and Gautam Sethi

The HDAC Inhibitor LBH589 Enhances the Antimyeloma Effects of the IGF-1RTK Inhibitor Picropodophyllin
Miguel Lemaire, Charlotte Fristedt, Prasoon Agarwal, Eline Menu, Els Van Valkenborgh, Elke De Bryune, Anders Osterborg, Peter Atadja, Olle Larsson, Magnus Axelson, Ben Van Camp, Helena Jernberg-Wiklund, and Karin Vanderkerken

Improved Efficacy of Dendritic Cell–Based Immunotherapy by Cutaneous Laser Illumination
Xinyuan Chen, Qiyan Zeng, and Mei X. Wu

Cytokine BAFF Gene Variation Is Associated with Survival of Patients with T-cell Lymphomas
Kan Zhai, Xiaobo Tian, Chen Wu, Ning Lu, Jiang Chang, Liming Huang, Tongwen Zhang, Yuling Zhou, Yan Qiao, Dianke Wu, Wen Tan, Jieping Chen, and Dongxin Lin

Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review
Xiaoyun Liao, Teppie Morikawa, Paul Lochhead, Yu Imamura, Aya Kuchiba, Mai Yamamura, Katsuhiko Nosho, Zhi Rong Qian, Rebecca Nash, Jeffrey A. Meyerhardt, Charles S. Fuchs, and Shi Ji Lin

cMET and Phospho-cMET Protein Levels in Breast Cancers and Survival Outcomes
Kanwal P. Baghlan, Wenting Wang, Shuyong Liu, Mariana Chavez-MacGregor, Xiaolong Meng, Gabriel N. Hortobagyi, Gordon B. Mills, Funda Meric-Bernstam, George R. Blumenschein Jr, and Ana M. Gonzalez-Angulo

Tumor Epidermal Growth Factor Receptor and EGFR PY1068 Are Independent Prognostic Indicators for Head and Neck Squamous Cell Carcinoma

Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
Josep M. Llovet, Carol E.A. Peña, Chetan D. Lathia, Michael Shan, Gerold Meinhard, and Jordi Bruix on behalf of the SHARP Investigators Study Group

The Use and Interpretation of Competing Risks Regression Models
James J. Dignam, Qiang Zhang, and Masha Kocherginsky
See commentary p. 2127

Resampling Phase III Data to Assess Phase II Trial Designs and Endpoints
Manish R. Sharma, Theodore G. Karrison, Yuyan Jin, Robert B. Ries, Michael L. Maitland, Walter M. Stadler, and Mark J. Ratain
See commentary p. 2130

The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
See commentary p. 2124

BRAF(V600) Inhibitor GSK2118436 Targeted Inhibition of Mutant BRAF in Cancer Patients Does Not Impair Overall Immune Competency
David S. Hong, Luis Vence, Gerald Falchook, Laszlo G. Radavanyi, Chengwen Liu, Vicki Goodman, Jeffrey J. Legos, Sam Blackman, Antonio Scambia, Razelle Kurzrock, Gregory Lizée, and Patrick Hwu
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>2344</td>
<td>A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors</td>
<td>Arun Rajan, Corey A. Carter, Ronan J. Kelly, Martin Gutierrez, Shivaani Kummur, Eva Szabo, Mary Ann Yancey, Juipeing Ji, Baskar Mannargudi, Sukyung Woo, Shawn Spencer, William Douglas Figg, and Giuseppe Giaccone</td>
</tr>
<tr>
<td>2352</td>
<td>Whole Blood Stem Cell Reinfusion and Escalated Dose Melphalan in Castration-Resistant Prostate Cancer: A Phase 1 Study</td>
<td>Jonathan Shamash, Jimmy Jacob, Samir Agrawal, Thomas Powles, Katherine Mutsvangwa, Peter Wilson, and Justin Stebbing</td>
</tr>
<tr>
<td>2374</td>
<td>Analyzing the Pivotal Trial That Compared Sunitinib and IFN-α in Renal Cell Carcinoma, Using a Method That Assesses Tumor Regression and Growth</td>
<td>Wilfred D. Stein, Julia Wilkerson, Sindy T. Kim, Xin Huang, Robert J. Motzer, Antonio Tito Fojo, and Susan E. Bates</td>
</tr>
<tr>
<td>2382</td>
<td>Connexin 47 Mutations Increase Risk for Secondary Lymphedema Following Breast Cancer Treatment</td>
<td>David N. Finegold, Catherine J. Baty, Kelly Z. Knickelbein, Shelley Perschke, Sarah E. Noon, Diana Campbell, Jenny M. Karlsson, Diana Huang, Mark A. Kimak, Elizabeth C. Lawrence, Eleanor Feingold, Stephen D. Meriney, Adam M. Bruisky, and Robert E. Ferrell</td>
</tr>
<tr>
<td>2391</td>
<td>Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib</td>
<td>Elizabeth A. Punnoose, Siminder Atwal, Weiquan Liu, Rajiv Raja, Bernard M. Fine, Brett G.M. Hughes, Rodney J. Hicks, Garret M. Hampton, Lukas C. Amler, Andrea Pirzkal, and Mark R. Lackner</td>
</tr>
<tr>
<td>2402</td>
<td>Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial</td>
<td>Maggie C.U. Cheang, David K. Voduc, Dongsheng Tu, Shan Jiang, Samuel Leung, Stephen K. Chia, Lois E. Shepherd, Mark N. Levine, Kathleen L. Pritchard, Sherri Davies, Inge J. Stijlemans, Carole Davis, Mark T.W. Ebbert, Joel S. Parker, Matthew J. Ellis, Philip S. Bernard, Charles M. Perou, and Torsten O. Nielsen</td>
</tr>
<tr>
<td>2413</td>
<td>Correction: GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained In Vivo Pathway Inhibition</td>
<td></td>
</tr>
</tbody>
</table>
ABOUT THE COVER

RAF265 greatly reduces the activation of MEK1 in melanoma patient tumors. Photomicrograph showing immunohistochemical localization of a remaining low level of active phospho-MEK1 (green) in a melanoma patient tumor that was treated with RAF265 after being implanted into a nude mouse. Nuclei are stained with DAPI and appear blue. 20X magnification. For details, see the article by Su and colleagues on page 2184 of this issue.